Universe Pharmaceuticals INC
UPC
$4.91
-$0.21-4.10%
NASDAQ
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -28.74% | -25.43% | -22.33% | -20.81% | -19.52% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -28.74% | -25.43% | -22.33% | -20.81% | -19.52% |
| Cost of Revenue | -22.92% | -14.28% | -4.84% | 7.20% | 20.50% |
| Gross Profit | -41.14% | -44.55% | -47.02% | -50.57% | -52.88% |
| SG&A Expenses | 18.58% | -8.24% | -25.63% | -44.33% | -56.79% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -98.55% | -80.78% | -63.51% | -34.68% | -7.13% |
| Total Operating Expenses | -14.42% | -21.13% | -26.62% | -25.14% | -23.76% |
| Operating Income | -102.21% | 0.58% | 41.39% | 43.65% | 46.68% |
| Income Before Tax | -87.66% | -63.67% | -54.26% | -12.25% | 45.80% |
| Income Tax Expenses | -73.07% | 6.20% | 1,208.48% | 365.93% | 199.52% |
| Earnings from Continuing Operations | -32.61% | -55.89% | -69.59% | -28.25% | 24.67% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -32.61% | -55.89% | -69.59% | -28.25% | 24.67% |
| EBIT | -102.21% | 0.58% | 41.39% | 43.65% | 46.68% |
| EBITDA | -117.91% | 0.46% | 43.57% | 46.25% | 49.93% |
| EPS Basic | -- | -- | -- | -- | -- |
| Normalized Basic EPS | -- | -- | -- | -- | -- |
| EPS Diluted | -- | -- | -- | -- | -- |
| Normalized Diluted EPS | -- | -- | -- | -- | -- |
| Average Basic Shares Outstanding | -- | -- | -- | -- | -- |
| Average Diluted Shares Outstanding | -- | -- | -- | -- | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |